Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
-
Published:2017-09
Issue:
Volume:82
Page:45-55
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Schadendorf DirkORCID, Long Georgina V., Stroiakovski Daniil, Karaszewska Boguslawa, Hauschild Axel, Levchenko Evgeny, Chiarion-Sileni Vanna, Schachter Jacob, Garbe Claus, Dutriaux Caroline, Gogas Helen, Mandalà Mario, Haanen John B.A.G., Lebbé Céleste, Mackiewicz Andrzej, Rutkowski Piotr, Grob Jean-Jacques, Nathan Paul, Ribas Antoni, Davies Michael A., Zhang Ying, Kaper Mathilde, Mookerjee Bijoyesh, Legos Jeffrey J., Flaherty Keith T., Robert Caroline
Subject
Cancer Research,Oncology
Reference30 articles.
1. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015 2. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N Engl J Med,2015 3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015 4. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015 5. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial;Hodi;Lancet Oncol,2016
Cited by
155 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|